Bupivacaine HCl

Catalog No.S2454

For research use only.

Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhythmias.

Bupivacaine HCl  Chemical Structure

CAS No. 18010-40-7

Selleck's Bupivacaine HCl has been cited by 4 Publications

Purity & Quality Control

Choose Selective Sodium Channel Inhibitors

Other Sodium Channel Products

Biological Activity

Description Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhythmias.
Targets
Sodium channel [4]
In vitro

Bupivacaine solution is cytotoxic to bovine articular chondrocytes and articular cartilage in vitro after only 15 to 30 minutes exposure. [1] Bupivacaine acts in isolated mitochondria, as uncouplers between oxygen consumption and phosphorylation of adenosine diphosphate. [2] Bupivacaine causes a concentration-dependent mitochondrial depolarization and pyridine nucleotide oxidation in isolated mitochondria, which are matched by an increased oxygen consumption at bupivacaine concentrations of 1.5 mm or less at pH 7.4, whereas respiration is inhibited at higher concentrations. Bupivacaine causes the opening of the permeability transition pore (PTP), a cyclosporin A-sensitive inner membrane channel that plays a key role in many forms of cell death. Bupivacaine causes mitochondrial depolarization and pyridine nucleotides oxidation that are matched by increased concentrations of cytosolic free Ca(2+), release of cytochrome c, and eventually, hypercontracture in intact flexor digitorum brevis fibers. [3] Bupivacaine inhibits GIRK channels within seconds of application, regardless of whether channels are activated through the muscarinic receptor or directly via coexpressed G protein G(beta)gamma subunits. Bupivacaine also inhibits alcohol-induced GIRK currents in the absence of functional pertussis toxin-sensitive G proteins. [4] Bupivacaine HCl also potently inhibits cAMP production with an IC50 of 2.3 μM.[6]

In vivo Bupivacaine does not only induce Ca2+ release from the sarcoplasmic reticulum (SR) in rats, but also inhibits Ca2+ uptake by the SR, which is mainly regulated by SR Ca2+ adenosine triphosphatase activity. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 65 mg/mL
(200.06 mM)
Ethanol 65 mg/mL
(200.06 mM)
Water 23 mg/mL
(70.79 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 324.89
Formula

C18H28N2O.HCl

CAS No. 18010-40-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05017584 Not yet recruiting Drug: Hyperbaric bupivacaine Pain Duke University February 2022 Phase 4
NCT05097118 Recruiting Drug: Ketamine Versus Bupivacaine Appendicitis Acute Sohag University September 1 2021 Early Phase 1
NCT05038956 Not yet recruiting -- Video-assisted Thoracic Surgery (VATS) University of Utah September 2021 --
NCT04685421 Recruiting Drug: Bupivacaine liposome Cardiac Conditions Nicklaus Children''s Hospital f/k/a Miami Children''s Hospital July 15 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Bupivacaine HCl | Bupivacaine HCl ic50 | Bupivacaine HCl price | Bupivacaine HCl cost | Bupivacaine HCl solubility dmso | Bupivacaine HCl purchase | Bupivacaine HCl manufacturer | Bupivacaine HCl research buy | Bupivacaine HCl order | Bupivacaine HCl mouse | Bupivacaine HCl chemical structure | Bupivacaine HCl mw | Bupivacaine HCl molecular weight | Bupivacaine HCl datasheet | Bupivacaine HCl supplier | Bupivacaine HCl in vitro | Bupivacaine HCl cell line | Bupivacaine HCl concentration | Bupivacaine HCl nmr